Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Telix To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Telix between February 21, 2025 and August 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - December 8, 2025) ...

NEW YORK, Dec. 8, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX). Shareholders who purchased shares of TLX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/telix-pharmaceuticals-ltd-loss-submission-form/?id=179723&from=4 CLASS PERIOD ...

NEW YORK, Dec. 5, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd." or the "Company") (NASDAQ: TLX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Telix Pharmaceuticals Ltd. investors who were adversely affected by alleged securities fraud between February 21, 2025 and August 28, 2025. Follow the link below to get more information and be contacted by a member of our team:https:// ...

NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd." or the "Company") (NASDAQ: TLX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Telix Pharmaceuticals Ltd. investors who were adversely affected by alleged securities fraud between February 21, 2025 and August 28, 2025. Follow the link below to get more information and be contacted by a member of our team: ht ...

Core Viewpoint - Telix Pharmaceuticals Ltd. is facing a class action lawsuit due to allegations of misleading investors regarding its prostate cancer therapeutic candidates and supply chain quality [1][2]. Group 1: Company Overview - Telix Pharmaceuticals Ltd. is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals [1]. Group 2: Class Action Details - The class period for the lawsuit is from February 21, 2025, to August 28, 2025 [1]. - The lawsuit was filed on behalf of investors who purchased or acquired Telix securities during the class period [1]. Group 3: Allegations - The complaint alleges that during the class period, defendants materially overstated the progress of Telix's prostate cancer therapeutic candidates, TLX591 and TLX592, as well as the quality of its supply chain and partners [2]. - Investors were reportedly surprised on July 22, 2025, when Telix disclosed an SEC investigation into its disclosures regarding the development of its prostate cancer therapeutic candidates [3]. - On August 28, 2025, Telix announced it received a Complete Response Letter (CRL) from the FDA, citing deficiencies in chemistry, manufacturing, and controls, and requested additional data for the drug product used in the phase 3 clinical trial [3]. Group 4: Impact on Stock - Following the announcement of the SEC investigation and the CRL from the FDA, the price of Telix's American Depositary Shares (ADSs) declined [3].

Core Viewpoint - Rosen Law Firm is encouraging investors of Telix Pharmaceuticals Ltd. to secure legal counsel before the January 9, 2026 deadline for a securities class action lawsuit related to the company's misleading statements during the class period from February 21, 2025 to August 28, 2025 [1][5]. Group 1: Legal Action Details - Investors who purchased Telix securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by January 9, 2026 [3][6]. - The lawsuit alleges that Telix's defendants made materially false statements regarding the company's progress in prostate cancer therapeutics and the quality of its supply chain, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked highly for its number of securities class action settlements and has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - The article discusses a securities class action lawsuit against Telix Pharmaceuticals Ltd, alleging that the company and its executives misrepresented the progress of their prostate cancer drug candidates TLX591 and TLX592, as well as the reliability of their third-party manufacturing partners, leading to significant stock declines [1]. Regulatory Failures - On July 22, 2025, Telix disclosed an SEC subpoena related to the development of TLX591 and TLX592, raising questions about misleading disclosures regarding drug development progress [1]. - On August 28, 2025, the FDA issued a Complete Response Letter (CRL) rejecting the Zircaix (TLX250-CDx) application due to deficiencies in Chemistry, Manufacturing, and Controls (CMC), along with documented Form 483 deficiencies at third-party manufacturers [1]. Stock Impact - Following the regulatory revelations, Telix's American Depositary Shares (ADSs) experienced a sharp decline, including a 21% drop after the final regulatory news [1]. - The lawsuit claims that investors who purchased TLX ADSs during the class period (February 21, 2025 – August 28, 2025) may be entitled to damages due to the undisclosed issues [1]. Legal Proceedings - The deadline for investors to move the court for appointment as lead plaintiff in the class action lawsuit is January 9, 2026 [1]. - Hagens Berman, the law firm leading the litigation, is actively advising affected investors and has a history of securing substantial recoveries for investors [1].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Telix Pharmaceuticals Ltd. regarding a class action lawsuit due to alleged misleading statements made by the company during a specified class period [1][3]. Group 1: Allegations - The complaint alleges that Telix Pharmaceuticals materially overstated its progress with prostate cancer therapeutic candidates [3]. - It is claimed that the company overstated the quality of its supply chain and partners [3]. - As a result of these misstatements, the company's statements about its business, operations, and prospects were deemed materially false and misleading [3]. Group 2: Class Action Details - The class period for the lawsuit is from February 21, 2025, to August 28, 2025 [3]. - Shareholders are encouraged to register for the class action by January 9, 2026, to participate in potential recovery [4]. - There is no cost or obligation for shareholders to register and participate in the case [4]. Group 3: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - Rosen Law Firm is encouraging investors of Telix Pharmaceuticals Ltd. to secure legal counsel before the January 9, 2026 deadline for a securities class action lawsuit related to the company's alleged misleading statements during the class period from February 21, 2025, to August 28, 2025 [1][5]. Group 1: Class Action Details - Investors who purchased Telix securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by January 9, 2026 [3]. - The lawsuit claims that Telix's management made materially false statements regarding the progress of its prostate cancer therapeutic candidates and the quality of its supply chain, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked No. 1 for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of the Plaintiffs' Bar by Law360 in 2020 [4].

Core Viewpoint - Telix Pharmaceuticals Ltd. is facing a securities class action lawsuit due to regulatory setbacks and significant stock declines, prompting an investigation into potential securities fraud [1][6]. Summary by Relevant Sections Class Action Details - The class action lawsuit, titled Thomas v. Telix Pharmaceuticals Ltd., aims to represent investors who purchased the company's securities between February 21, 2025, and August 28, 2025 [2]. - The lawsuit alleges that Telix and its executives made false and misleading statements about the company's business, inflating its valuation before the truth was revealed [2]. Core Allegations - The lawsuit claims Telix violated the Securities Exchange Act of 1934 by failing to disclose critical information regarding regulatory issues [3]. - Two major events led to a significant decline in Telix's American Depositary Shares (ADSs): 1. The FDA issued notices of deficiency to third-party manufacturing partners, contradicting earlier assurances about supply chain reliability [3]. 2. Following this news, Telix's ADSs dropped over 21% in value over two trading sessions [4]. Specific Misrepresentations - Management allegedly overstated the progress and commercial prospects of prostate cancer therapeutic candidates TLX591 and TLX592 [5]. - The company misrepresented the stability and regulatory compliance of its third-party supply chain, which was crucial for regulatory applications [5]. Regulatory Events Impacting Stock - The first significant stock drop occurred after Telix disclosed receiving a subpoena from the SEC on July 22, 2025, leading to a more than 13% decline in ADS price over two trading sessions [5]. - The second major blow came on August 28, 2025, when Telix received a Complete Response Letter from the FDA for TLX250-CDx, identifying deficiencies in the Chemistry, Manufacturing, and Controls package [5]. Investigation and Legal Proceedings - Hagens Berman is actively investigating the claims, focusing on discrepancies between the company's assurances and the regulatory revelations [7]. - The firm is looking into whether Telix knowingly misrepresented its drug development and manufacturing capabilities [7].